Journal of Pharmacology, Genetics and Molecular Biology (JPGMB)
ISSN: 3049-3757 | Vol. 01, Issue-05, Sep-Oct, 2025

Antioxidants Function in The Treatment of Chronic Kidney Disease

Raviraj Ramrao More[1*], Pooja Sanjay Naik[2], Amit A Mulje[3], Gaurav Jain[3]

[1]Maharashtra College of Pharmacy, Nilanga, 413521

[2]NBS Institute of Pharmacy, Ausa Dist – Latur

[3]IES Institute of Pharmacy, IES University, Bhopal-462044, Madhya Pradesh, India

***Corresponding Author E-mail: advaitpanu@gmail.com**

ABSTRACT

Chronic kidney disease (CKD) is a progressive disorder, which is associated with progressive loss of renal functionality, having oxidative stress as one of the key mechanisms that contribute to inflammation, fibrosis, and tissue damage. Studies on animals have been becoming increasingly interested in the therapeutic value of antioxidants in alleviating these pathogenic events. This review summarizes the evidence available on natural antioxidants, such as vitamins, polyphenols and flavonoids, and synthetic antioxidants, such as N-acetylcysteine and enzymatic mimetics, such as Tempol, in preclinical models of CKD. The evidence suggests that these agents are useful in reducing reactive oxygen species, increasing endogenous antioxidant defenses, preserving mitochondrial functions, and regulating pro-inflammatory, pro-fibrotic signaling pathways, which reduce renal injury and improve its functions. Comparative analysis has revealed that natural antioxidants present multi-targeted protection with limitations on bioavailability, synthetic antioxidants give strong intracellular protection mainly in renal tissues and enzyme mimetics have both renal and systemic cardiovascular effects. Even with these positive results, animal models, dosages, and long-term research are variable, thus making translation a problem. This review highlights the possibility of antioxidant therapy as an adjunctive intervention in the management of CKD and the need to have standard preclinical studies to maximize its efficacy and ease its future use in the clinical scene.

Key Words:

Chronic Kidney Disease, CKD, Oxidative Stress, Antioxidants, N-Acetylcysteine, Tempol, Polyphenols, Flavonoids, Renal Protection

Article History:

Received on July 18, 2025

Revised on Aug 29, 2025

Accepted on Sep 27, 2025

Published on Oct 13, 2025

DOI: https://doi.org/10.64062/JPGMB.Vol1.Issue5.3

1. INTRODUCTION

Chronic kidney disease (CKD) can be described as an emerging global health crisis since it is characterized by a progressive reduction in kidney function, and further development to end-stage renal disease, unless treated. Oxidative stress has risen to become one of the key players among the various factors that lead to the CKD progression[1].



Figure 1: Chronic Kidney Diseases[2]

Oversupply of reactive oxygen species (ROS) overwhelms the inherent antioxidant defenses of the body resulting in cell damage, inflammation, and fibrosis in the kidneys. During the last ten years there has been an increase of interest in the therapeutic potential of antioxidants as preclinical research in the use of animal models to counteract these harmful processes[3]. Renal-protective effects have been shown to be promising by natural products, such as vitamins and polyphenols, synthetic compounds (such as N-acetylcysteine) and enzymatic mimetics (such as Tempol). This review will help to summarize existing animal-based information regarding the topic of antioxidant therapy in CKD and offer insights into the mechanisms of action, comparative effectiveness, and future prospects in regard to translational research.

1.1.Background Information and Context

Chronic kidney disease (CKD) is a chronic and irreversible disease that is marked by a gradual impairment of renal functioning. CKD has a high morbidity and mortality, and a high burden on health care as millions of persons are affected by the condition worldwide[4]. Oxidative stress is one of the distinct characteristics of CKD that can be defined as a disproportion between the generation of reactive oxygen species (ROS) and the ability of endogenous antioxidant defense system, such as superoxide dismutase (SOD), catalase, and glutathione peroxidase (GPx). High levels of ROS in renal tissues have the potential to result in lipid peroxidation, protein oxidation, DNA damage, and mitochondrial dysfunction, which leave tubular injury, glomerulosclerosis, interstitial fibrosis, and inflammation, in their wake.

The use of the experimental animal models of CKD including 5/6 nephrectomy rats, adenine-induced CKD mice, cisplatin-induced nephrotoxicity and streptozotocin-induced diabetic nephropathy models has been effectively used to elucidate how oxidative stress and renal injury occurs[5]. The models enable a regulated environment to assess the effectiveness of therapeutic interventions to reverse the effects of oxidative damages and retard CKD progression.

1.2.Objectives of the Review

This review aims to:

1. To examine the molecular mechanisms by which oxidative stress contributes to CKD pathophysiology.

2. To evaluate the efficacy of various antioxidants, including natural compounds (vitamins, polyphenols, flavonoids), synthetic agents (N-acetylcysteine), and enzymatic mimetics (Tempol), in animal models of CKD.
3. To analyze the strengths, limitations, and comparative effectiveness of these antioxidants.
4. To identify gaps in preclinical research and propose directions for future studies to improve translational potential.

1.3.Importance of the Topic

The use of antioxidants in CKD is of utmost importance since oxidative stress can be recognized as one of the major contributors of disease progression and complications such as cardiovascular dysfunction[6]. Although the contemporary clinical treatment is mostly aimed at regulating blood pressure, glycemia and proteinuria, it is expected that the antioxidant adjunct measures can directly target the pathogenic mechanisms. Preclinical research provides mechanistic understanding that must be utilized towards the ability to develop safe and effective therapeutic regimens on CKD patients[7]. This paper intends to summarize existing information by analyzing evidence on animals with the objective of enhancing the possibility of transamination and future research to incorporate antioxidant therapy into the treatment of CKD.

2. OXIDATIVE STRESS IN CKD PATHOPHYSIOLOGY

It has become evident that oxidative stress has become a focus pathological factor that leads to chronic kidney disease (CKD) as indicated in numerous animal models. It is caused by a lack of balance between excess production of reactive oxygen species (ROS) and reactive nitrogen species (RNS) and lack of activity of the endogenous antioxidant defenses, such as superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GPx). The resulting redox imbalance derails cellular homeostasis causing oxidative destruction of proteins, nucleic acids, and lipids, and thereby hastens the development of renal injury and the onset of end-stage kidney disease[8].

Evidence from Experimental Models

→ **5/6 Nephrectomy Rat Models**

This model which is a simulation of progressive renal failure has been critical in offering important information. There are increased malondialdehyde (MDA), which is a lipid peroxidation biomarker, indicating widespread oxidative stress on cell membranes. Meanwhile, SOD and CAT activity have been significantly reduced, and this reduces the capacity of the kidney to counteract the superoxide radicals and hydrogen peroxide. These changes are strongly associated with glomerulosclerosis, interstitial fibrosis, and tubular atrophy, the histological characteristics of the CKD development.



Figure 2: 5/6 Nephrectomy Rat Models[9]

→ **Adenine-Induced CKD in Mice**

Adenine treatment results in deposition of 2,8-dihydroxyadenine crystal in the renal tubules causing obstruction and inflammation of tubules. In addition to crystal-induced damage, oxidative stress is increased by increased activity of NADPH oxidase (NOX4) which is a primary enzyme source of ROS in kidney tissue[10]. At the same time, mitochondrial malfunction inhibits oxidative phosphorylation and ATP production, leading to leakage of electrons of electron transport chain and subsequent production of ROS. This twofold blow, NOX4 overactivation and mitochondrial impairment, results in a cycle of amplified ROS and inflammation and fibrosis.

→ **Nephrotoxic and Metabolic Models**

- High ROS generation in cisplatin-induced nephrotoxicity (rat models) leads to the depletion of glutathione (GSH) and the activation of mitochondrial-apoptotic-pathways, both leading to tubular necrosis and defective renal filtration.

Simultaneously, models of streptozotocin-induced diabetic nephropathy indicate that the chronic hyperglycemia condition causes ROS through advanced glycation end products (AGEs) and polyol pathway activation, which worsen oxidative damage of glomerular and tubular cells.

The CKD Molecular Pathways of ROS

ROS do not only cause cells damage but are also signaling molecules that enhance renal pathology:

- **NF-KB Activation:** NF-KB signaling stimulated by ROS induces transcription of pro-inflammatory cytokines (TNF- α, IL- 6, IL- 1b) resulting in chronic renal inflammation[11].

- **TGF-β1/Smad Pathway Upregulation:** Transforming growth factor- beta1 (TGF- 1) is a master regulator of fibrosis triggered by oxidative stress that leads to excess extracellular matrix (ECM) deposition and scarring.
- **Mitochondrial Dysfunction:** Depletion of the mitochondrial membrane potential and disruption of electron transfer augments the release of ROS, which contributes to apoptosis and necrosis of renal tubular cells.

In such a way, the triad of pathogenic impacts of CKD is created by oxidative stress:

- Direct cellular damage (lipid peroxidation, DNA/protein damage),
- Necrosis, inflammation (NF- -kaB activation),
- Fibrosis (TGF-β1 upregulation).

Table 1 summarizes the evidence of the role of oxidative stress in CKD based on studies in different animals[12]. These papers emphasize that besides a direct effect of damaging renal cells, ROS further induce pro-inflammatory and pro-fibrotic signaling pathways, which contribute to chronic inflammatory and fibrosis, and progressive renal dysfunction. The table contains the information about the animal models, experimental procedures, the origin of the oxidative stress, and the main pathological observations in every study.

Table 1: Evidence of Oxidative Stress in CKD Animal Models

Author's Name	Animal Model	Method / Model	Source of Oxidative Stress	Key Findings
Casanova et al., 2021[13]	5/6 Nephrectomy Rats	Surgical removal of 5/6 of kidney mass	Reduced SOD, CAT; increased MDA	Severe glomerulosclerosis, interstitial fibrosis, tubular atrophy
Dennis & Witting, 2017[14]	Adenine-Induced CKD Mice	Oral administration of adenine (0.2–0.75% in diet)	NADPH oxidase (NOX4), mitochondrial injury	Crystal deposition, mitochondrial dysfunction, ROS amplification, renal fibrosis
Small et al., 2012[15]	Cisplatin-Induced Nephrotoxicity (Rats)	Intraperitoneal injection of cisplatin	Glutathione depletion, mitochondrial ROS	Tubular necrosis, apoptosis, impaired renal function
Eugenio-Pérez et al., 2016[16]	Diabetic Nephropathy (Rats)	Streptozotocin (STZ) injection to induce hyperglycemia	Hyperglycemia → AGEs, polyol pathway	Increased oxidative stress, glomerular injury, albuminuria

3. NATURAL ANTIOXIDANTS IN CKD MODELS

Natural antioxidants, such as vitamins and polyphenolic compounds, have been widely investigated in animal models of chronic kidney disease (CKD) in terms of their capability to prevent oxidative stress, inflammation and fibrosis. These compounds can perform several actions and they are direct scavengers of reactive oxygen species (ROS), stimulate endogenous antioxidant defenses, regulate inflammatory signaling, and mitochondrion protection. Preclinical trials suggest a good chance of their effectiveness in decelerating the process of CKD[17].

3.1.Vitamin E and Vitamin C

Classical antioxidant vitamins with documented effects in the prevention of renal protection in experimental CKD models are vitamin E (2 -tocopherol) and vitamin C (ascorbic acid). Vitamin E supplementation in rat models of adenine induced CKD, lipid peroxidation, which was measured by the reduction in malondialdehyde (MDA) level, and renal functions, such as serum creatinine, blood urea nitrogen (BUN), and creatinine clearance, were significantly improved. Vitamin E protects cell membranes against oxidative stress on lipids, proteins and nucleic acids, and maintains tubular and glomerular integrity[18].

Vitamin C, when used individually or together with Vitamin E, increased the intracellular antioxidant capacity by increasing the levels of reduced glutathione (GSH), which is an important endogenous antioxidant. This resulted in a reduction of the tubular necrosis and better histological characteristics of the kidney such as reduction in interstitial fibrosis and glomerular sclerosis. Nevertheless, some of the studies indicated that, under specific circumstances, Vitamin C or E in high doses may be counterproductive, and may produce ROS, especially when metal ions are present or in end-stage CKD, and that it should be carefully dosed and monitored.

3.2.Polyphenols

Resveratrol, curcumin and catechins contained in green tea are poly-phenolic compounds which attract attention because of their multi-target antioxidant, anti-inflammatory, and anti-fibrotic effects. Not only do they scavenge free radicals but these compounds also regulate the important signaling pathways that have been found to be involved in the CKD progression.



Figure 3: Main Types of Polyphenols[19]

- ✓ **Resveratrol:** In 5/6 nephrectomy rat models, resveratrol exhibited significant renal protective effects via activation of the SIRT1 (sirtuin 1) signaling pathway that is linked to cell resistance to stress, mitochondrial biogenesis, and anti-inflammatory control. Resveratrol inhibited the activity of NF-kB inhibiting transcription of pro-inflammatory cytokines TNF-a, IL-1b, and IL-6. This bilateral antioxidant and anti-inflammatory effect led to a better renal histology, less glomerulosclerosis and maintained tubular architecture. Resveratrol also improved mitochondrial activities and decreased apoptosis in renal tubular cells, which indicates that it promotes cellular homeostasis of cellular energy.
- ✓ **Curcumin:** In streptozotocin-induced nephropathy in diabetic rats, curcumin supplementation had Reno protective effect by reducing proteinuria and TGF- B1 expression and preventing extracellular matrix deposition in the kidney. Curcumin controlled certain pathways such as fibrosis, oxidative stress and inflammation pathways, such as inhibition of NF-KB and activation of native antioxidant enzymes like superoxide dismutase (SOD) and catalase[20]. Histologic examination showed that there were less glomerular hypertrophy, less mesangial expansion, and less interstitial fibrosis, which showed that curcumin might reverse the effects of early and progressive CKD pathology.
- ✓ **Green Tea Catechins:** At least the catechins of green tea such as Epigallocatechin-3-gallate (EGCG) and other catechins have been shown to be protective in the cisplatin induced nephrotoxicity models. Catechins enhanced the work of mitochondria by maintaining the mitochondrial membrane potential and lowering the production of ROS in renal tubular cells. They also prevented apoptosis by up-regulating pro- and anti-apoptotic proteins like Bax and Bcl-2 and also by reducing tubular necrosis and interstitial inflammation. Also, catechins inhibited the activation of NF- 2 -mediated by

oxidative stress, thus restraining the inflammatory cascade and facilitating renal tissue conservation.

4. SYNTHETIC AND ENZYMATIC ANTIOXIDANTS

Enzymatic and synthetic antioxidants have a role to play in the management of CKD since they are capable of either restoring antioxidant reserves, or imitating the effect of natural antioxidant enzymes. Synthetic and enzymatic antioxidants are made to provide more precise, stronger and stable effects that are used to neutralize reactive oxygen species (ROS) compared to natural antioxidants (vitamins, polyphenols). There is substantial evidence in studies using animal models that these compounds decrease the tension of oxidation, lower tissue damage to the kidney and enhance system performance in CKD[21].

4.1. N-Acetylcysteine (NAC)

One of the thiol-containing antioxidants is N-acetylcysteine (NAC) which is one of the most researched. It is a major precursor of glutathione (GSH), the most found intracellular antioxidant, and directly serves as a scavenger of hydroxyl radicals, hydrogen peroxide and hypochlorous acid.

Evidence from Animal Models:

In ischemia-reperfusion (I/R) rat models, NAC treatment was found to be a significant inhibitor of oxidative injury, which decreased malondialdehyde (MDA) activities and restored GSH levels in the kidney tissues. This biochemical impact corresponded into reduced tubular apoptosis, maintained renal histoarchitecture and enhanced renal blood flow thus alleviating acute injury that has frequently advanced into CKD[22].

- The prevention of ROS overproduction and lipid peroxidation in the cisplatin induced nephrotoxicity rat models by the NAC supplementation, and the augmentation of antioxidant enzyme catalase (CAT) and superoxide dismutase (SOD). Notably, NAC safeguarded renal mitochondria and prevented depolarization of mitochondrial membrane potential and induction of apoptosis.
- NAC decreased albuminuria, inhibited glomerular hypertrophy, and inhibited nuclear factor-kappa B (NF- kB)-type pathway stimulation in models of diabetic nephropathy, which implicates it as a dual antioxidant and anti-inflammatory agent.

Mechanism of Action in CKD (Animal Findings):

- Increases the production of intracellular glutathione, or the antioxidant defense of the kidney.
- ROS Deactivation, reducing oxidative stress.
- The repression of NF-kB-induced inflammatory cascades, the release of cytokines.
- Preservation of mitochondrial activity, inhibition of tubular cells apoptosis and necrosis.

In general, there is a powerful animal evidence that NAC prevents acute and chronic renal damage, as it acts against oxidative and inflammatory cascades[23].

4.2. Tempol (SOD Mimetic)

Tempol is a stable nitroxide radical which replicates the action of superoxide dismutase (SOD), which is one of the most important antioxidant enzymes in the body. Tempol alleviates the oxidative stress at the point of origin by catalyzing the dismutation of superoxide anions ($O_2^{\bullet -}$).



Figure 4: Tempol- Therapeutic Antioxidant for CKD Animal Model [24]

Evidence from Animal Models:

- Tempol treatment of adenine-induced CKD rat models recovered antioxidant enzyme activities (SOD, CAT, GPx) in kidney, which caused a decreased systemic oxidative stress. Amazingly, Tempol was able not only to maintain renal functioning, but also to reduce blood pressure and vascular oxidative stress and exhibited systemic protective activity, which was not limited to the kidney.
- However, Tempol treatment prevented vascular stiffness and left ventricular hypertrophy in 5/6 nephrectomy rat models, and enhanced endothelial function, which demonstrates that its antioxidant effects give left ventricular cardiorenal protection during CKD.
- Tempol inhibited the excessive ROS generation in the renal tissues, and also decreased proteinuria or normalization of nitric oxide (NO) bioavailability in salt-sensitive rat models with hypertension, and these effects emphasized its importance in vascular and renal hemodynamics.

Mechanism of Action in CKD (Animal Findings):

1. SOD-mimetic activity by which superoxide is eliminated to decrease the peroxynitrite formation and lipid peroxidation[25].
2. Recovery of NO bioavailability, and subsequent enhancement of renal blood flow and vasodilation.
3. Lessening of general oxidative stress in the blood, which leads to a decrease in blood pressure.
4. Prevention of vascular and heart tissue, lessening the complications of CKD, like a cardiovascular disease caused by hypertension.

Therefore, the use of Tempol as an SOD mimetic has an exclusive therapeutic benefit in CKD because it combats vascular dysfunction, renal oxidative stress, and systemic complications.

4.3. Comparative Perspective

Table 2: Effects of Synthetic Antioxidants on Oxidative Stress in CKD Animal Models[26]

Antioxidant	Primary Mechanism	Animal Models Used	Key Outcomes
N-Acetylcysteine (NAC)	Boosts glutathione, direct ROS scavenger, anti-inflammatory	Ischemia-reperfusion, cisplatin-induced nephrotoxicity, diabetic nephropathy	Reduced oxidative damage, restored renal blood flow, decreased apoptosis, attenuated fibrosis
Tempol (SOD mimetic)	Mimics superoxide dismutase, restores NO bioavailability	Adenine-induced CKD, 5/6 nephrectomy, salt-sensitive hypertension	Restored antioxidant enzymes, lowered blood pressure, reduced vascular oxidative stress, protected against cardiorenal damage

NAC primarily reinforces intracellular antioxidant status, and offers selective protection to the kidney, especially on acute oxidative attacks. Tempol has systemic advantages, both renal oxidative stress and cardiovascular complications related to CKD. A combined body of evidence (symbiosis) on animal models indicates that synthetic and enzymatic antioxidants can not only be useful in alleviating oxidative injury but can be used to enhance long-term outcomes in CKD in combination with natural antioxidants or other standard therapies.

5. COMPARATIVE EVALUATION OF ANTIOXIDANT EFFICACY

The antioxidant therapeutic potential of antioxidants on chronic kidney disease (CKD) has been investigated widely in animal models[27]. These analyses repeatedly show that oxidative stress can be used to reduce renal injury and maintain the stability of all kidney functions and enhance system outcomes, such as vascular and cardiovascular health. The effectiveness of antioxidants however varies according to their category: natural antioxidants, synthetic compounds and enzymatic mimetics. Comparison of these agents helps in gaining knowledge on their mechanisms and limitations, strengths and translational opportunities.

5.1.Natural Antioxidants

Natural antioxidants, vitamins (E and C), polyphenols like resveratrol and curcumin, catechins of green tea have been extensively investigated in CKD animal models (5/6 nephrectomy rats), adenine induced CKD mice and diabetic nephropathy models[28].

- **Mechanisms of Action**

These are multifunctional compounds. They scavenging reactive oxygen species (ROS) and regulating the effects of signaling in inflammation and in fibrosis. Indicatively, curcumin suppresses the TGF-b1/Smad signaling pathway, which decreases extracellular matrix deposition, whereas resveratrol is the activator of SIRT1, which improves mitochondrial biogenesis and inhibits apoptosis. The catechins preserve the functionality of mitochondrion and vitamins such as E inhibit lipid peroxidation, which stabilizes cell membranes.

- **Strengths**

The natural antioxidants are usually safe and well tolerated because they are of dietary origin. Their multi-targeted actions enable them to focus on multiple pathogenic events of CKD such as oxidative stress, inflammation, and mitochondrial dysfunction[29].

- **Limitations**

Despite all these, natural antioxidants have low bioavailability and high metabolic rates thereby decreasing their efficacy in therapy. Vitamin C and E used in high doses have paradoxical pro-oxidant effects and their protective effects are usually restricted to those at an early stage of CKD. Natural antioxidants cannot be relied on to repair damage in advanced disease which is full of fibrosis and scarring.

5.2. Synthetic Antioxidants

Synthetic antioxidants are intended to supplement endogenous antioxidant defenses directly (such as by replenishing the levels of intracellular glutathione) with the primary aim of acting as N-acetylcysteine (NAC)[30].

- **Mechanisms of Action**

NAC is a cysteine donor that enhances the production of GSH, but also it directly removes ROS. It suppresses the NF-Kb pathway, which in turn lowers the generation of pro-inflammatory cytokine TNF-a and IL- 6. Moreover, NAC maintains mitochondrial activity and stops apoptosis and tubular necrosis.

- **Strengths**

There is animal research which has shown that NAC can significantly decrease the oxidative biomarkers which include malondialdehyde (MDA) in ischemia-reperfusion and cisplatin-induced nephrotoxicity and diabetic nephropathy models. It is effective in prevention of tubular cell apoptosis, inflammation and reinstatement of renal blood flow and gives robust renal protection.

- **Limitations**

The biological half-life of NAC is not very long and, therefore, dosing has to be repeated. Its effectiveness may also differ according to the disease model and dose regimen. There is a difference between the benefit of NAC and enzymatic mimetics, like Tempol; NAC is characterized by renal protection and limited benefits of the systemic cardiovascular.

5.3. Enzymatic Antioxidants

An example of enzymatic mimetics, Tempol, mimics or enhances the activity of antioxidant enzymes that are part of the endogenous antioxidant system, such as superoxide dismutase (SOD)[31].

- **Mechanisms of Action**

Tempol facilitates the process of dismutating the superoxide anions into molecules that are not that harmful, thereby minimizing the sources of ROS. It enhances the vascular endothelial performance by replenishing the bioavailability of nitric oxide (NO) and decreasing hypertension. Tempol also has a systemic antioxidant effect on the body other than the kidney, where it helps to prevent the oxidative damage of cardiovascular tissues.

- **Strengths**

In the animal models of CKD, such as adenine-induced and 5/6 nephrectomy models, Tempol enhances the renal function rates, decreases vascular oxidative stress, and returns the blood pressure to normal rates. It is especially useful in CKD that is characterized by cardiovascular complications, because of its more systemic effects.

- **Limitations**

Tempol is not a stable chemical and needs proper formulation so as not to lose its effectiveness. The safety data are scarce in the long term, and its systemic effects require dose optimization to avoid off-target effects.

5.4. Comparative Insights

In general, natural antioxidants are safe and multi-targeted, but limited to bioavailability and dependency with the disease stage. Synthetic antioxidants like NAC have strong intracellular protection especially in acute or early CKD, but only have a weak systemic advantage. Enzymatic mimetics such as Tempol are broadly protecting such as renal and cardiovascular tissues but have stability and chronic administration issues.

Table 3: Comparative Overview of Antioxidant Efficacy in CKD Animal Models[32]

Antioxidant Type	Key Examples	Mechanisms	Strengths	Limitations
Natural	Vitamin E, Vitamin C, Resveratrol, Curcumin, Catechins	ROS scavenging, anti-inflammatory, anti-fibrotic	Safe, multi-targeted, mitochondrial protection	Poor bioavailability, stage-limited, pro-oxidant risk
Synthetic	N-acetylcysteine (NAC)	GSH booster, direct ROS scavenger, NF-κB inhibition	Consistent renal protection, reduces apoptosis, restores blood flow	Short half-life, limited systemic effects, dose-dependent efficacy
Enzymatic Mimetics	Tempol (SOD mimetic)	Superoxide dismutation, NO restoration	Renal and cardiovascular protection, systemic antioxidant effects	Stability issues, limited long-term data, dosing challenges

6. DISCUSSION

Chronic kidney disease (CKD) is a multifactorial disease with oxidative stress being the primary driver of renal injury, inflammation and fibrosis. It has been established in animal studies that overload of endogenous antioxidant systems by excessive reactive oxygen species (ROS), results in progressive structural and functional damage to the kidneys. The preclinical evidence shows that not only natural and synthetic antioxidants and enzymatic mimetics can prevent these oxidative attacks, keep renal activity, and regulate the pathogenic signaling pathways[33]. This discussion summarizes the results of the different animal models, interpreting the mechanism of antioxidant action, assessing their therapeutic value, and determining the gaps and future research in order to translate the findings to clinical use in the treatment of CKD.

6.1. Interpretation and Analysis of Findings

The animal research shows with consistency that oxidative stress is one of the pivotal processes in the pathogenesis and progression of chronic kidney disease (CKD). Natural and synthetic antioxidants, enzymatic mimetics, are effective in reducing the effects of oxidative damage, inflammation, and fibrotic remodeling in kidney tissues[34].

Multi-targeted mechanisms are multi-target mechanisms of action by natural antioxidants, including resveratrol, curcumin, and green tea catechins. Not only do they scavenge reactive oxygen species (ROS), they also regulate essential signal transduction pathways, such as NF-kB and TGF-β1, and thus, inhibiting inflammation and fibrosis. Lipid membrane stabilization and antioxidant effects are seen in vitamins E and C although at high doses they have paradoxical pro-oxidant effects.

Examples of synthetic antioxidants include N-acetylcysteine (NAC), which provide specific intracellular antioxidant protection through the restoration of glutathione (GSH), antioxidant activity, and mitochondrial homeostasis. NAC had a regular decrease in the amount of oxidative biomarkers, constrained tubular apoptosis, and enhanced renal hemodynamics in models of ischemia-reperfusion, cisplatin-induced nephrotoxicity, and diabetic nephropathy[35].

The use of enzymatic mimetics such as Tempol has shown systemic effect by imitating the activity of superoxide dismutases (SOD) and restoring the bioavailability of nitric oxide (NO) and protecting the vascular and cardiac tissues and renal structures. The dual renal and cardiovascular protective properties of Tempol highlight the role of dealing with both the local and systemic oxidative stress in CKD.

In comparison to natural antioxidants, the natural antioxidants are harmless and multi-purpose but depend on bioavailability and dependency on the disease stage. NAC has strong intracellular protection properties with the main benefits in the renal system, and Tempol has more extensive systemic benefits but needs to be carefully formulated and evaluated in terms of long-term safety.

6.2. Implications and Significance

The preclinical results also have a number of implications of clinical significance in the CKD management:

1. **Mechanistic Insight:** Animal researches explain how the particular molecular pathways antioxidants provide protection to kidneys such as ROS scavenging, anti-inflammatory signaling, and anti-fibrotic pathways. This mechanistic knowledge can direct some specific therapeutic approaches in CKD[36].
2. **Multi-Modal Therapy Potential:** It is believed that natural, synthetic and enzymatic antioxidants have complementary activity and thus that combination therapy will be more effective than monotherapy. As an example, NAC may be used to protect the intracellular renal cells whereas Tempol might also be used to handle the whole-body cardiovascular stress.
3. **Preventive and Early Intervention:** Since natural antioxidants demonstrate higher efficacy in the early phase of CKD, antioxidant treatment can have the greatest effect in case of an intervention before the huge fibrosis and irreversible damage.

4. **Translational Relevance:** Human trials have not completely confirmed these results but the steady beneficial effects that are seen in animal models show the possibility of creating antioxidant-based adjunct therapies in clinical management of CKD.

6.3.Gaps in Current Research

Although the results of preclinical studies of antioxidants in CKD are promising, there are a number of gaps:

1. **Animal Model Variability:** Many different models of CKD are used including 5/6 nephrectomy, adenine-induced CKD, cisplatin-induced nephrotoxicity, diabetic nephropathy, among others, which are potentially inappropriate because of their pathological, disease progression and ROS dynamics differences[37].
2. **Absence of Standardized Protocols:** The inconsistency in the dosing of antioxidants and the duration of the treatment, as well as the route, complicates direct comparisons of the studies.
3. **Long-Term Efficacy:** The vast majority of the studies are short-term and mainly evaluate interventions at an initial stage. The impacts of antioxidants on the progression of CKD, survival, and late-stage renal pathology have not been well studied.
4. **Systemic vs. Renal-Specific Effects:** Not many studies fully assess the systemic effects like cardiovascular protection, metabolic or immunomodulation and renal efficacy[38].
5. **Molecular Mechanisms:** Although the main signaling pathways, such as NF -B and TGF-B1, are well-investigated, the cross-talk between oxidative stress, mitochondrial dynamics, autophagy, and the fibro genic signaling in CKD is poorly understood.

6.4. Future Research Directions

Future preclinical research needs to be done in order to fill these gaps by:

1. **Standardization of Animal Models:** Consistent CKD models and guidelines of administering antioxidants will enhance the reproducibility and translatability.
2. **Combination Therapies:** The exploration of synergistic interactions between natural, synthetic, and enzymatic antioxidants can contribute to the increased efficacy and is capable of addressing multiple pathogenic processes at once[39].
3. **Long-term and Stage-specific Studies:** Comparing antioxidants in the early and late CKD condition, and their impact on fibrosis development, renal functioning and survival.
4. **Mechanistic Elucidation:** Molecular pathways and mitochondrial bioenergetics, autophagy, and epigenetic regulation will be more thoroughly examined to have a wider understanding of the antioxidant action in CKD.
5. **Systemic and Cardiovascular Effects:** Assessments of vascular function, blood pressure, and cardiac remodeling should be examined in the preclinical studies to be able to understand the full therapeutic potential of antioxidants in CKD.
6. **Translational Issues:** Dose optimization and enhancement of bioavailability and stability of antioxidants, especially in the systemic administration should be considered to enable safe and effective translation to human therapy[40].

7. CONCLUSION

The review illustrates the central role of oxidative stress in chronic kidney disease (CKD) development and the therapeutic potential of antioxidants in the reduction of renal damage,

inflammation, and fibrosis. Animal model evidence shows that natural antioxidants (vitamins, polyphenols and flavonoid), synthetic agents (N-acetylcysteine) and enzymatic mimetic agents (Tempol) have the capacity to mitigate oxidative damage, keep renal functioning intact and enhance systemic outcomes. Although natural antioxidants are safe and multi-targeted, synthetic and enzymatic antioxidants are strong intracellular and systemic antioxidants. Although preclinical data are encouraging, animal model variability, dose schedules and limited chronic studies suggest the need to adopt standard protocols and more research on the same. Combination therapies, stage-specific intervention, and mechanistic elucidation should be investigated in the future to streamline antioxidant strategies to be used in a translational study, and ultimately, a more effective adjunct treatment in the management of CKD should be created.

REFERENCES

1. Colombijn, J. M., Hooft, L., Jun, M., Webster, A. C., Bots, M. L., Verhaar, M. C., & Vernooij, R. W. (2023). Antioxidants for adults with chronic kidney disease. Cochrane Database of Systematic Reviews, (11).
2. Daenen, K., Andries, A., Mekahli, D., Van Schepdael, A., Jouret, F., & Bammens, B. (2019). Oxidative stress in chronic kidney disease. Pediatric nephrology, 34(6), 975-991.
3. Nasri, H. (2017). Antioxidant therapy to ameliorate chronic kidney disease induced by oxidative stress; an updated mini-review. Journal of Preventive Epidemiology, 2(1), e04-e04.
4. Rapa, S. F., Di Iorio, B. R., Campiglia, P., Heidland, A., & Marzocco, S. (2019). Inflammation and oxidative stress in chronic kidney disease—potential therapeutic role of minerals, vitamins and plant-derived metabolites. International journal of molecular sciences, 21(1), 263.
5. Sung, C. C., Hsu, Y. C., Chen, C. C., Lin, Y. F., & Wu, C. C. (2013). Oxidative stress and nucleic acid oxidation in patients with chronic kidney disease. Oxidative medicine and cellular longevity, 2013(1), 301982.
6. Dehghan Shahreza, F. (2017). Oxidative stress, free radicals, kidney disease and plant antioxidants. Immunopathol persa, 3(2), e11.
7. García-Sánchez, A., Miranda-Díaz, A. G., & Cardona-Muñoz, E. G. (2020). The role of oxidative stress in physiopathology and pharmacological treatment with pro-and

antioxidant properties in chronic diseases. Oxidative medicine and cellular longevity, 2020(1), 2082145.

8. Podkowińska, A., & Formanowicz, D. (2020). Chronic kidney disease as oxidative stress-and inflammatory-mediated cardiovascular disease. Antioxidants, 9(8), 752.
9. Zhang, X., Agborbesong, E., & Li, X. (2021). The role of mitochondria in acute kidney injury and chronic kidney disease and its therapeutic potential. International journal of molecular sciences, 22(20), 11253.
10. Nasri, H., & Rafieian-Kopaei, M. (2014). Protective effects of herbal antioxidants on diabetic kidney disease. Journal of research in medical sciences: the official journal of Isfahan University of Medical Sciences, 19(1), 82.
11. Keegan, R. F., & Webb, C. B. (2010). Oxidative stress and neutrophil function in cats with chronic renal failure. Journal of Veterinary Internal Medicine, 24(3), 514-519.
12. Trujillo, J., Chirino, Y. I., Molina-Jijón, E., Andérica-Romero, A. C., Tapia, E., & Pedraza-Chaverrí, J. (2013). Renoprotective effect of the antioxidant curcumin: Recent findings. Redox biology, 1(1), 448-456.
13. Casanova, A. G., López-Hernández, F. J., Vicente-Vicente, L., & Morales, A. I. (2021). Are antioxidants useful in preventing the progression of chronic kidney disease? Antioxidants, 10(11), 1669.
14. Dennis, J. M., & Witting, P. K. (2017). Protective role for antioxidants in acute kidney disease. Nutrients, 9(7), 718.
15. Small, D. M., Coombes, J. S., Bennett, N., Johnson, D. W., & Gobe, G. C. (2012). Oxidative stress, anti-oxidant therapies and chronic kidney disease. Nephrology, 17(4), 311-321.
16. Eugenio-Pérez, D., Medina-Fernández, L. Y., Saldivar-Anaya, J. A., Molina-Jijón, E., & Pedraza-Chaverri, J. (2016). Role of dietary antioxidant agents in chronic kidney. Free Radicals Dis, 1, 331.
17. Ruiz, S., Pergola, P. E., Zager, R. A., & Vaziri, N. D. (2013). Targeting the transcription factor Nrf2 to ameliorate oxidative stress and inflammation in chronic kidney disease. Kidney international, 83(6), 1029-1041.
18. Tasanarong, A., Vohakiat, A., Hutayanon, P., & Piyayotai, D. (2013). New strategy of α-and γ-tocopherol to prevent contrast-induced acute kidney injury in chronic kidney disease patients undergoing elective coronary procedures. Nephrology Dialysis Transplantation, 28(2), 337-344.
19. Yu, M., Kim, Y. J., & Kang, D. H. (2011). Indoxyl sulfate–induced endothelial dysfunction in patients with chronic kidney disease via an induction of oxidative stress. Clinical Journal of the American Society of Nephrology, 6(1), 30-39.
20. Miranda-Díaz, A. G., Pazarín-Villaseñor, L., Yanowsky-Escatell, F. G., & Andrade-Sierra, J. (2016). Oxidative stress in diabetic nephropathy with early chronic kidney disease. Journal of diabetes research, 2016(1), 7047238.
21. Coppolino, G., Leonardi, G., Andreucci, M., & Bolignano, D. (2018). Oxidative stress and kidney function: a brief update. Current pharmaceutical design, 24(40), 4794-4799.
22. Vodošek Hojs, N., Bevc, S., Ekart, R., & Hojs, R. (2020). Oxidative stress markers in chronic kidney disease with emphasis on diabetic nephropathy. Antioxidants, 9(10), 925.

23. Ali, B. H., Al-Salam, S., Al Suleimani, Y., Al Kalbani, J., Al Bahlani, S., Ashique, M., ... & Schupp, N. (2018). Curcumin ameliorates kidney function and oxidative stress in experimental chronic kidney disease. Basic & Clinical Pharmacology & Toxicology, 122(1), 65-73.

24. Gwozdzinski, K., Pieniazek, A., & Gwozdzinski, L. (2021). Reactive oxygen species and their involvement in red blood cell damage in chronic kidney disease. Oxidative medicine and cellular longevity, 2021(1), 6639199.

25. Kennedy, D. J., Wilson Tang, W. H., Fan, Y., Wu, Y., Mann, S., Pepoy, M., & Hazen, S. L. (2017). Diminished antioxidant activity of high-density lipoprotein–associated proteins in chronic kidney disease. Journal of the American Heart Association, 2(2), e000104.

26. Nuhu, F., Seymour, A. M., & Bhandari, S. (2019). Impact of intravenous iron on oxidative stress and mitochondrial function in experimental chronic kidney disease. Antioxidants, 8(10), 498.

27. Jiménez-Osorio, A. S., García-Niño, W. R., González-Reyes, S., Álvarez-Mejía, A. E., Guerra-León, S., Salazar-Segovia, J., ... & Pedraza-Chaverri, J. (2016). The effect of dietary supplementation with curcumin on redox status and Nrf2 activation in patients with nondiabetic or diabetic proteinuric chronic kidney disease: a pilot study. Journal of Renal Nutrition, 26(4), 237-244.

28. Liakopoulos, V., Roumeliotis, S., Bozikas, A., Eleftheriadis, T., & Dounousi, E. (2019). Antioxidant supplementation in renal replacement therapy patients: is there evidence?. Oxidative medicine and cellular longevity, 2019(1), 9109473.

29. Modaresi, A., Nafar, M., & Sahraei, Z. (2015). Oxidative stress in chronic kidney disease. Iranian journal of kidney diseases, 9(3).

30. Mokhtari, Z., Hekmatdoost, A., & Nourian, M. (2017). Antioxidant efficacy of vitamin D. Journal of Parathyroid Disease, 5(1).

31. Ni, D., Jiang, D., Kutyreff, C. J., Lai, J., Yan, Y., Barnhart, T. E., ... & Cai, W. (2018). Molybdenum-based nanoclusters act as antioxidants and ameliorate acute kidney injury in mice. Nature communications, 9(1), 5421.

32. Piko, N., Bevc, S., Hojs, R., & Ekart, R. (2023). The role of oxidative stress in kidney injury. Antioxidants, 12(9), 1772.

33. de Almeida Alvarenga, L., de Oliveira Leal, V., Borges, N. A., de Aguiar, A. S., Faxén-Irving, G., Stenvinkel, P., ... & Mafra, D. (2018). Curcumin-A promising nutritional strategy for chronic kidney disease patients. Journal of Functional Foods, 40, 715-721.

34. Chauveau, P., Aparicio, M., Bellizzi, V., Campbell, K., Hong, X., Johansson, L., ... & European Renal Nutrition (ERN) Working Group of the European Renal Association–European Dialysis Transplant Association (ERA-EDTA). (2018). Mediterranean diet as the diet of choice for patients with chronic kidney disease. Nephrology Dialysis Transplantation, 33(5), 725-735.

35. Gimblet, C. J., Kruse, N. T., Geasland, K., Michelson, J., Sun, M., Ten Eyck, P., ... & Jalal, D. (2024). Curcumin supplementation and vascular and cognitive function in chronic kidney disease: A randomized controlled trial. Antioxidants, 13(8), 983.

36. Noels, H., Lehrke, M., Vanholder, R., & Jankowski, J. (2021). Lipoproteins and fatty acids in chronic kidney disease: molecular and metabolic alterations. Nature Reviews Nephrology, 17(8), 528-542.

37. Vaziri, N. D. (2016). HDL abnormalities in nephrotic syndrome and chronic kidney disease. Nature Reviews Nephrology, 12(1), 37-47.

38. Sharifi-Rad, M., Anil Kumar, N. V., Zucca, P., Varoni, E. M., Dini, L., Panzarini, E., ... & Sharifi-Rad, J. (2020). Lifestyle, oxidative stress, and antioxidants: back and forth in the pathophysiology of chronic diseases. Frontiers in physiology, 11, 552535.

39. Agharazii, M., St-Louis, R., Gautier-Bastien, A., Ung, R. V., Mokas, S., Larivière, R., & Richard, D. E. (2015). Inflammatory cytokines and reactive oxygen species as mediators of chronic kidney disease-related vascular calcification. American journal of hypertension, 28(6), 746-755.

40. Fu, Q., Colgan, S. P., & Shelley, C. S. (2016). Hypoxia: the force that drives chronic kidney disease. Clinical medicine & research, 14(1), 15-39.